Scarica l'app Stockscreener
25.05
0.36%
-0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.14
Aprire:
$25.4
Volume 24 ore:
40.13M
Relative Volume:
1.00
Capitalizzazione di mercato:
$142.77B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
19.21
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
+3.64%
1M Prestazione:
-3.36%
6M Prestazione:
-2.34%
1 anno Prestazione:
+1.91%
Intervallo 1D:
$24.97
$25.65
Intervallo di 1 settimana:
$24.14
$25.65
Portata 52W:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.05 | 143.28B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,179.11 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.04 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.49 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.50 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.76 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? - The Motley Fool
How the Pfizer building scare could push developers to rethink vertical conversion plans - The Real Deal
Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research - simplywall.st
Pfizer stock holds support as shares await fresh catalyst - ad-hoc-news.de
Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story? - Kalkine Media
Engineers blame lack of steel reinforcement on Pfizer HQ structural failure - The Real Deal
Dividend Roundup: JPMorgan Chase, Coca-Cola, Johnson & Johnson, Pfizer, and more - Seeking Alpha
McDonald's vs. PfizerThe Better Retirement Stock Isn't the One You'd Guess - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV) and Pfizer (PFE) - The Globe and Mail
Pfizer stock holds steady as recent earnings and pipeline updates shape investor expectations - ad-hoc-news.de
Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer - simplywall.st
Form 4 Pfizer For: 16 July By Investing.com - Investing.com Canada
EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - Reuters
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Exclusive-Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - WTAQ
Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View - Yahoo Finance
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now? - Yahoo Finance
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update - marketscreener.com
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech - marketscreener.com
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Arbutus and Genevant file patent lawsuits against Pfizer, BioNTech - Investing.com
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Pfizer captive Blue Whale Re holds A rating amid hard market participation - Insurance Business
Pfizer stock holds steady as pipeline and patent cycle shape long-term outlook - ad-hoc-news.de
Pfizer Abrysvo by Pfizer Inc.RSV vaccine targets seniors and pregnant women - Ad Hoc News
Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue - TechStock²
Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)? - simplywall.st
Sanofi sues Pfizer, Moderna over COVID shot technology - Reuters
Pfizer building’s column scare tests Midtown East’s biggest conversion bet - The Real Deal
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Reuters
Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties - Bloomberg Law News
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC - Yahoo Finance
AM Best Affirms Credit Ratings of Blue Whale Re Ltd. - Business Wire
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? - 24/7 Wall St.
Prevnar 13 by Pfizer Inc.pneumococcal vaccine quietly powering a key franchise - Ad Hoc News
PFE Stock Quote Price and Forecast - CNN
Pfizer’s EPS Has Fallen 65% From Its Peak, Here’s Why That Might Be the Point - TIKR.com
Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech - Law360
Structural Failure at Pfizer Conversion Project Triggers Citywide Construction Review - Propmodo
Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen - Yahoo Finance
How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom - Law360
Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump - simplywall.st
A week after the old NYC Pfizer building buckled, what’s new? - PIX11
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen - 24/7 Wall St.
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried? - The Globe and Mail
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results - Zacks Investment Research
Here's What to Expect From Pfizer's Next Earnings Report - Yahoo Finance
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
Pfizer (NYSE:PFE) Holds 7% Yield as AI Selloff Hits, Options Traders Look for Protection - TechStock²
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.48%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):